Amgen to Invest $600M in New Science & Innovation Center at HQ
PorAinvest
martes, 2 de septiembre de 2025, 10:13 am ET1 min de lectura
AMGN--
The new facility will feature advanced automation and digital capabilities, providing scientists with the necessary tools and environment to drive scientific excellence and innovation in biotechnology. This investment is part of Amgen's broader commitment to U.S. innovation and reflects the company's substantial investment in manufacturing and research and development since the passage of the Tax Cuts and Jobs Act (TCJA) of 2017. The company has already committed over $40 billion to these efforts, including over $5 billion in direct capital expenditures in the U.S. [1]
The new center will enhance Amgen's global network of sites, leveraging decades of operational expertise and technological advancements. The construction is expected to create hundreds of U.S. jobs, contributing to the local economy and supporting the company's ongoing efforts to advance human health. This investment builds on recent expansions, including a $900 million manufacturing facility expansion in Central Ohio and a $1 billion investment for a second manufacturing plant in Holly Springs, North Carolina.
Amgen's commitment to innovation and investment in the U.S. is evident in its recent recognition as one of the "World's Most Innovative Companies" by Fast Company and "America's Best Large Employers" by Forbes. The company's forward-looking statements emphasize the potential risks and uncertainties associated with its strategic initiatives, including collaborations, acquisitions, and the impact of regulatory environments and global economic conditions.
References:
[1] https://www.marketscreener.com/news/amgen-investing-more-than-half-a-billion-dollars-in-new-state-of-the-art-center-for-science-and-inn-ce7c50d3de8ff725
Amgen plans to invest over $600 million in a new science and innovation center at its U.S. HQ in Thousand Oaks, California. The center will empower scientists with collaborative tools and environments to drive scientific discovery and advance human health. Construction is set to begin in Q3 2025 and will create hundreds of U.S. jobs. The investment reflects Amgen's commitment to American science and innovation.
Amgen Inc. (NASDAQ: AMGN) has announced a significant investment of more than $600 million in a new state-of-the-art center for science and innovation at its global headquarters in Thousand Oaks, California. The center, slated to commence construction in the third quarter of 2025, is designed to foster collaboration among researchers, engineers, and scientists across various disciplines, with the goal of accelerating the discovery of next-generation therapeutics for patients with serious diseases.The new facility will feature advanced automation and digital capabilities, providing scientists with the necessary tools and environment to drive scientific excellence and innovation in biotechnology. This investment is part of Amgen's broader commitment to U.S. innovation and reflects the company's substantial investment in manufacturing and research and development since the passage of the Tax Cuts and Jobs Act (TCJA) of 2017. The company has already committed over $40 billion to these efforts, including over $5 billion in direct capital expenditures in the U.S. [1]
The new center will enhance Amgen's global network of sites, leveraging decades of operational expertise and technological advancements. The construction is expected to create hundreds of U.S. jobs, contributing to the local economy and supporting the company's ongoing efforts to advance human health. This investment builds on recent expansions, including a $900 million manufacturing facility expansion in Central Ohio and a $1 billion investment for a second manufacturing plant in Holly Springs, North Carolina.
Amgen's commitment to innovation and investment in the U.S. is evident in its recent recognition as one of the "World's Most Innovative Companies" by Fast Company and "America's Best Large Employers" by Forbes. The company's forward-looking statements emphasize the potential risks and uncertainties associated with its strategic initiatives, including collaborations, acquisitions, and the impact of regulatory environments and global economic conditions.
References:
[1] https://www.marketscreener.com/news/amgen-investing-more-than-half-a-billion-dollars-in-new-state-of-the-art-center-for-science-and-inn-ce7c50d3de8ff725

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios